Диссертация (1139649), страница 49
Текст из файла (страница 49)
366. – P. 1290–1295.196.Effect of BCG vaccination against Mycobacterium tuberculosis infection inchildren: systematic review and meta-analysis / A. Roy, M. Eisenhut, R.J. Harris[et al.] // Brit. Med. J. – 2014. – Vol. 349. – P.467–470.197.Engineering of in vivo immune responses to DNA immunization viacodelivery of costimulatory modecule genes / J.J. Kim, M.L. Bagarazzi, N.Trivedy [et al.] // Nature Biotechnology. - 1997.
– Vol. 15. – P. 641–646.198.Enhanced protection against tuberculosis by vaccination with recombinant304Micobacterium microtti vaccine that induces T cell immunity against region ofdifference 1 antigens / P. Brodin, L. Majilessi, R. Brosh [et al.] // J.
Infect. Dis. –2004. –Vol. 190. – P. 115–122.199.ESAT-6 subunit vaccination against Mycobacterium tuberculosis / L.Brandt, M. Elhay, I. Rosenkrands [et al.] // Infect. Immun. – 2000. – Vol. 68. – P.791–795.200.Evaluation of the safety and immunogenicity of a candidate tuberculosisvaccine, MVA85A, delivered by aerosol to the lungs of macaques / A.D.
White,L. Sibley, M.J. Dennis [et al.] // Clin. Vaccine Immunol. – 2013. – Vol. 20. – P.663–672.201.Expert Committee on Biological Standardisation: Technical report seriesN 329 / World Health Organ. – Geneva, 1966. – Report N 18. – 132 p.202.Fine, P.E. Transmissibility and persistence of oral polio vaccine viruses:implications for the global poliomyelitis eradication initiative / P.E.
Fine, I.A.Carneiro // Amer. J. Epidemiol. – 1999. - Vol. 150, N 10. – P. 1001–1021.203.Fischer, A. Severe combined immunodeficiencies (SCID) / A. Fisher //Clin. Exp. Immunol. – 2000. - Vol. 122. – P. 143–149.204.Floyd, K. Financial resources required for TB control to achieve globaltargets set for 2015 / K. Floyd, A.
Pantoja // Bull. World Health Organ. - 2008. –Vol. 86. – P. 568–576.205.Frick, M. The TB vaccines pipeline: where are we going, where have webeen? / M. Frick // I-Base / Treatment Action Group: 2013 pipeline report / P.Clayden, S. Collins, C. Daniels [et al.]; Ed. by Andrea Benzacar. - New York:Treatment Action Group, 2013. - P.
263–283. - Available from: http://www.pipelinereport.org/. (Accessed April 10, 2014).206.Futher studies on single radial immunodiffusion. Quntitative analysis ofrelated and unrelated antigens / G. Manchini, D.K. Nacb, G.S. Heremans [et al.] //Immunochem. – 1970. – Vol. 7. – P. 261–264.207.Genetic basis of patients with bacille Calmette-Guerin osteomyelitis inJapan: identification of dominant partial interferon-gamma receptor 1 deficiency305as a predominant type / Y. Sasaki, A. Nomura, K.
Kusahara [et al.] // J. Infect.Dis. – 2002. - Vol. 185, N 5. – P. 706–709.208.Gheorghiu, M. Maintenance and control of the French BCG strain 1173p2(primary and secondary seed-lots) / M. Gheorghiu, J. Augier, P.H. Lagrange //Bull. de l'Institut Pasteur. – 1983. - Vol. 81. – P. 281–288.209.Gheorghiu, M. The present and future role of BCG vaccine in tuberculosiscontrol / M. Gheorghiu // Biologicals.
- 1990. - Vol. 18, № 2. - P. 135 - 141.210.Global tuberculosis: report 2014 / World Health Organ. - Availableat:http://www.who.int/tb/publications/global_report/en/.211.Goraya, J.S. Bacille Calmette-Guerin lymphadenitis / J.S. Goraya, V.S.Virdi // Postgrad. Med. J. – 2002. - Vol.
78, N 920. – P. 327–329.212.Guerin, N. Actualisacion des connaissances sur le BCG indications enEurope et dans les pays en developpment / N. Guerin, D. Levy-Bruhl // Med.Trop. (Fr). - 1996. - Vol. 56, № 2. - P. 173–176.213.Harboe, M. MPB70, a unique antigen of Mycobacterium bovis BCG / M.Harboe, S. Nagai // Amer. Rev. Resp. Dis. – 1984. – Vol. 129, N 3. – P.
444–452.214.Harmonisation of TB control in the WHO European region: the history ofthe Wolfheze Workshops / J. Veen, G.B. Migliori, M. Raviglione [et al.] // Eur.Resp. J. – 2011. – Vol. 37. – P. 950–959.215.Hart, P.D. BCG and vole bacillus vaccines in the prevention of tuberculosisin adolescence and early adult life.
Final report to the Medical Research Council /P.D. Hart, I. Sutherland // Brit. Med. J. – 1977. – Vol. 30, N 2. – P. 293–295.216.Hatherill, M. Safety and immunogenicity of MVA85A prime and bacilleCalmette-Guérinboostvaccination(MVA(TB)029)/M.Hatherill.-http://www.clinicaltrials.gov/ct2/show/NCT1650389 (accessed Jan 29, 2013).217.Heimbeck, J. Surla vaccination preventive de la tuberculose par injectionsouscutanee de BCG chez les eleves infirmieres de lhopital Ulleval a Oslo(Norvege) / J. Heimbeck // Ann.
Inst. Pasteur. – 1929. – Vol. 43. – P. 1229–1232.306218.Hugosson,C.DisseminatedBCG-osteomyelitisincongenitalimmunodeficiency / C. Hugosson, H. Harfi // Pediatr. Radiol. – 1991. – Vol. 21. –P. 384–385.219.Increasedvaccineefficacyagainsttuberculosisofrecombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secretelisteriolysin / L. Grode, P. Seiter, S. Baumann [et al.] // J. Clin. Invest. – 2005. –Vol. 115, N 9. – P. 2472–2479.220.Infectious Disease Research Institute (Press Release). AERAS andIDRI Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine.2012 May 9.
- Available from:http://www.idri.org/press-5-9-12.html.221.Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancingbetween protection and lung pathology / J.A. Tree, A. Williams, S. Clafk [et al.] //Clin. Exp. Immunol. – 2004. – Vol.138, N 3. – P. 405–409.222.Intrapulmonary Mycobacterium avium infection as the first manifestationof chronic granulomatous disease / S. Ohga, K.
Ikeuchi, R. Kadoya [et al.] // J.Infect. - 1997. - Vol. 34. - P. 147–150.223.Iron-co-factoredsuperoxidedismutaseinhibitshostresponsesto Mycobacterium tuberculosis / К.M. Edwards, M.H. Cynamon, R.K. Voladri [etal.] // Amer. J. Resp. Crit. Care Med. – 2001. – Vol. 164. – P. 2213–2219.224.Issues relating to the use of BCG in immunization programmes: adisscusion document / P.E.M.
Fine, I.A.M. Carneiro, J.B. Milstien, C.J. Clements;World Health Organ. - Geneva, 1999. – 45 p.225.Kaufmann, S.H. Fact and fiction in tuberculosis vaccine research: 10 yearslater / S.H. Kaufman // Lancet Infect. Dis. – 2011. – Vol. 11.
– P. 633–640.226.Kaufmann, S.H. Future vaccination strategies against tuberculosis: thinkingoutside the box / S.H. Kaufman // Immunity. – 2010. – Vol. 33. – P. 567–577.227.Kaufmann, S.H., Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review Lancet / S.H. Kaufman, C. Lange, M.Rao // Resp. Med. – 2014. – Vol. 2. – P. 301–320.307228.Kaufmann, S.H. Tuberculosis vaccines: time for a global strategy / S.H.Kaufman, T.G. Evans, W.A. Hanekom // Sci Transl. Med. – 2015. – Vol.
7. – P.1–3.229.Knight, G.M., Impact and cost-effectiveness of new tuberculosis vaccinesin low- and middle-income countries / G.M. Knight, U.K. Griffiths, T. Summer //Proc. Nat. Acad. Sci. – 2014. –Vol. 111. – P. 15520–15525.230.Lalvani, A. Tuberculosis vaccines: time to reset the paradigm? // A.Lalvani, S.
Sridar, C.F. von Reyn // Thorax. – 2013. – Vol. 68. – P. 1092–1094.231.Lessons learnt in Europe on tuberculosis surveillance, outbreaks and BCGvaccination in 2011 / M.J. Van der Werf, F. Blasi, J. Giesecke [et al.] // Eur. Resp.J. – 2013. – Vol. 41. – P. 767–771.232.Long-term efficacy of BCG vaccine in American Indians and Alaskanatives: a 60-year follow-up study / N.F. Aronson, M. Santosham, G,W.Comstock [et al.] // J. Amer.
Med. Assoc. – 2004. – Vol. 291, N 17. – P. 2086–2091.233.Lugosi, L. Genetic transformation of BCG / L. Lugosi, W. Jacobs, B.Bloom // Tubercle. - 1988. - Vol. 70, № 3. - P. 159–170.234.Lymph node swelling due to bacille Calmette-Guerin vaccination withmultipuncture method / T. Mori, Y.
Yamauchi, K. Shiozawa // Tuber. Lung Dis. 1996. - Vol. 77, № 3. - P. 269–273.235.Mackaness, G.B. Immune response to different strains and preparations /G.B. Mackaness, D.J. Auclair, P.H. Lagrange // J. Natl. Cancer Inst. - 1973. –Vol. 51, N 5. – P. 1655–1667.236.Making BCG vaccination programmes safer in the HIV era / T.K. Mak,A.C.
Hesseling, G.D. Hussey [et al.] // Lancet. – 2008. – Vol. 372. – P. 786–787.237.McShane, H. Tuberculosis vaccines: beyond bacilli Calmette-Guérin / H.McShane // Philos. Trans. R. Soc. Lond B Biol. Sci. – 2011. – Vol. 12, N366(1579). – P. 2782–2789.238.Milstien, J. Guality control of BCG vaccines by the WHO: a review offactors that may influence vaccine effectiveness and safety / J.
Milstien, J. Gibson308// Bull. World Health Organ. - 1990. - Vol. 68, № 1. - P. 67–83.239.Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine,is safe in adolescents and children, and induces polyfunctional CD4+ T cells / T.J.Scriba, M. Tameris, N. Mansoor [et al.] // Eur. J. Immunol. – 2010. – Vol. 40. – P.279–290.240.Molecular analysis of genetic differences between Mycobacterium bovisBCG and virulent M. bovis / G.G.
Mahrias, P.J. Sabo, M.J. Hickey [et al.] // J.Bacteriol. – 1996. – Vol. 178. – P. 1274–1282.241.Mtb72f: a multi-subunit tandemly linked recombinant polyprotein protectsmice, guinea pigs and monkeys against virulent Micobacterium tuberculosischallenge / Y.A.W. Skeiky, M.R. Alderson, A. Campos-Neto [et al.] // TB 2000 –ASM conference on tuberculosis: past, present and future: abstr.
– New York,2000. - P. 35–35.242.Murray, C.J. Global, regional, and national incidence and mortality forHIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for theGlobal Burden of Disease Study 2013 / C.J. Murray, K.F. Ortblad, C. Guinovart //Lancet. – 2014. – Vol. 384. – P. 1005–1070.243.Mycobacterial diseases in primary immunodeficiencies / J. Reichenbach, S.rosenzweig, R. Doffinger [et al.] // Curr. Opin Allegry Clin. Immunol. – 2001. Vol. 40.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
